CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Medical Battery Market to Reach US$ 3,146.57 Million by 2033 | Astute Analytica

The market is rapidly advancing, driven by the demand for smaller, more powerful batteries for wearable and remote monitoring ...

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio-Antibiotic is primarily used for ...
The Bakersfield Californian

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company ...

Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio ...
TipRanks on MSN

Liquidia Technologies Secures Licensing Deal with Vectura

An announcement from Liquidia Technologies ( ($LQDA) ) is now available. On October 27, 2025, Liquidia Technologies entered into an exclusive ...
NBC4 WCMH-TV

Central Ohio nonprofits feeling pinch from government shutdown

An organization that has been a staple in the community for more than 100 years had to furlough its employees amid funding delays. Luckily, the closure was ...

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW ...